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22 :3 L13–L18Epigenetic dysregulation and poorer
prognosis in DAXX-deficient
pancreatic neuroendocrine tumoursDear Editor,Exome sequencing of sporadic pancreatic neuroendocrine
tumours (PNETs) has identified mutually exclusive muta-
tions in the chromatin regulators a-thalassaemia/mental
retardation X-linked (ATRX) and death-associated protein6
(DAXX) genes in 43% of cases (18 and 23% of cases
respectively in 68 cases studied) (Elsa¨sser et al. 2011, Jiao
et al. 2011). ATRX and DAXX are chromatin remodellers;
their loss leads to alternative lengthening of telomeres
(ALT) and chromosomal instability (CIN) (Heaphy et al.
2011). ALT is a telomerase-independent mechanism for
the maintenance of telomere stabilisation. Although it
was initially reported that ATRX/DAXX mutant tumours
had superior 10-year survival and outcome (Jiao et al.
2011), a recent larger study on 243 tumours demonstrated
that ATRX and DAXX loss and associated ALT in PNETs
correlates with CIN, advanced tumour stage, the develop-
ment of metastases and poorer progression-free survival
(PFS) and overall survival (OS) (Marinoni et al. 2014).
ATRX interacts with DNA methyltransferases 3A and
3L (DNMT3A/3L), known as ATRX-DNMT3A-DNMT3L
(ADD) (Hashimoto et al. 2010). DNMT3A and its accessory
protein, DNMT3L, contain a histone H3 lysine 4 (H3K4)
methyl-interacting ADD domain which links DNA
methylation with unmodified H3K4. This interaction is
one of the three described protein domains that provide a
functional link between DNA methylation and histone
modification. These interactions are pivotal for maintain-
ing accurate replication of histone methylation patterns in
newly replicated chromatin and in the subsequent fidelity
of gene expression. ATRX interacts directly with DAXX,
which functions as a chaperone for the deposition of
the histone variant H3.3 at repeat sequences across the
genome, including CpG islands and telomeric, pericentric
and ribosomal repeats (Clynes et al. 2013). DAXX is a
highly specific histone chaperone that discriminates H3.3
from other H3 variants. Mutually exclusive mutations in
ATRX and DAXX are also found in neurological tumours,
including neuroblastomas, paediatric glioblastomas,http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0108
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Printed in Great Britainoligodendrogliomas and medulloblastomas (Clynes et al.
2013). Notably, H3.3 is mutated in paediatric glioblastoma
and bone tumours, and H3.3 mutations are often
associated with changes in global DNA methylation
(Salomoni 2013, Maze et al. 2014).
Because of the known interaction between ATRX and
DNMT3A/3L and the interplay between ATRX and DAXX,
it is likely that PNETs with a loss of these tumour
suppressor genes would have different genome-wide
DNA methylation patterns as compared to those tumours
that retain this function.
In this study, we sought to determine the
genome-wide DNA methylation and copy number aberra-
tion profiles in ATRX/DAXX-positive and ATRX/DAXX-
negative PNETs using the Infinium 450K HumanMethyla-
tion BeadArray (Illumina Inc., San Diego, CA, USA).
Only ATRX/DAXX-positive tumours and tumours
with a loss of either ATRX or DAXX were considered.
Included in the study were 12 age-matched, normal
control pancreatic tissue samples (endocrine and
exocrine) because of the extreme rarity of isolated
pancreatic islet cell samples. Cases that showed hetero-
geneous ATRX or DAXX loss were also excluded so as to
avoid difficulties in drawing firm conclusions.
In total, 53 formalin-fixed paraffin-embedded tumour
specimens (46 primaries and seven liver metastases
from 39 cases) were included in this study (Fig. 1A). Of
these, 27 specimens (51%) had lost either ATRX (nZ9;
33%) or DAXX (nZ18; 67%) protein expression, as
determined by immunohistochemistry (Anti-ATRX
(SAB4502258) and Anti-DAXX (HPA008736) antibodies
(both rabbit polyclonal) were provided by Sigma–Aldrich).
Endothelial cells that stained positive for ATRX and DAXX
served as the internal control in each immunochemistry
section from cases that lacked expression of the corre-
sponding protein. Seven of 26 (27%) low-grade primary
tumours (G1, ki-67 of!2%) exhibited ATRX/DAXX loss as
compared to 13 of 19 (68%) intermediate-grade tumoursThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Full clinical and survival data and number of samples per
case are further provided in Table 1.
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grade of the primary tumour that gave rise to metastasis.
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Figure 1
(A) Details of the study cohort. (B and C) Kaplan–Meier survival curves for
ATRX- and DAXX-negative cases (nZ17) as compared to ATRX/DAXX-
positive cases (nZ17) and ATRX-negative (nZ8) and DAXX-negative (nZ9)
cases analysed independently and compared to ATRX/DAXX-positives cases
respectively. The 5-year PFS was 85% for positive cases, 52% for ATRX-
negative cases and 16% for DAXX-negative cases. (D) Unsupervised cluster
analysis using the top 1000 MVPs that showed segregation of ATRX-
negative (in green) and DAXX-negative (in orange) tumours as compared
to normal pancreatic tissue. Of the six ATRX/DAXX-negative tumour
samples (from six cases) that clustered with the normal control pancreatic
samples, only one case (G1, DAXX-negative) progressed (PFS 51 months),
and two cases had no follow-up data. Of the six metastatic samples
included in this study, two of them (both DAXX-negative) had a
matched G1 tumour sample. One of them grouped tightly with the G1
primary tumour. DNA methylation values (b-value 0–1) are represented
using a colour scale, where yellowZlow methylation and blueZhigh
methylation. Samples are shown on the x-axis, and probes are shown on
the y-axis. (E) Confirmation of tumour segregation primarily by grade and
then by ATRX or DAXX status using the top 1000 MVPs. (F) Copy number
variation (CNV) profiles associated with low and intermediate PNETs. The
top panel demonstrates increasing CNV across the genome for low-grade
(G1, ki-67!2%) tumours, with the least CNV occurring in the ATRX/DAXX-
positive primary (left). Increasing CNV alterations are seen in the
ATRX/DAXX-negative tumour (middle) and most CNV alterations occur in
the ATRX/DAXX-negative G1 liver metastasis (right). The same is observed
in intermediate grade (G2, ki-67 3–20%) tumours in the bottom panel.
Segmented copy numbers are shown as a red line, and sequential
chromosomes are shown in green and black (chr. 1–22).
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22 :3 L15(G2, ki-67 2–20%) (PZ0.008, Fisher’s exact test). One G3
and six of seven metastatic specimens also exhibited
ATRX/DAXX loss.
Survival analysis was based on 34 cases with
available follow-up data (eight ATRX-negative, nine
DAXX-negative, and 17 ATRX/DAXX-positive cases;
Table 1). Data were not available for two DAXX-negative
and one ATRX/DAXX-positive case. Case 37 (counted
twice), which had both ATRX-negative and ATRX/DAXX-
positive samples, was also excluded. Analysis of the
ATRX/DAXX-negative cases demonstrated that eight
cases (five DAXX-negative and three ATRX-negative
cases) progressed within 5 years of follow-up, whereas
nine cases (four DAXX-negative and five ATRX-negative
cases) did not. The majority of positive cases (13 of 17)
remained progression-free over the period of study. Poorer
5-year PFS was observed in ATRX-negative and DAXX-
negative cases as compared to ATRX/DAXX-positive cases
(PZ0.0009) (Fig. 1B). When ATRX-negative and DAXX-
negative cases were analysed independently, a loss of
DAXX led to a significantly poorer PFS at 5 years (DAXX
loss: 16%, PZ0.0005; ATRX loss: 52%, PZ0.15; and no loss
85% 5-year PFS; Fig. 1C). All P values were obtained using
a Cox regression model.
Depending on the different pair-wise comparisons,
certain samples that had been assigned to unique arrays
had to be removed to allow for the correction of the batch-
to-batch variation which occurs when running the
Illumina 450K HumMeth array. Comparison between all
ATRX/DAXX-negative and ATRX/DAXX-positive tumours
identified 58 methylation-variable positions (MVPs). Inde-
pendent comparisons of either DAXX-negative (nZ18) or
ATRX-negative (nZ7) with ATRX/DAXX-positive tumours
(nZ23) revealed 4352 MVPs and 34 differentially methyl-
ated regions (DMRs) and 258 MVPs and one DMR
respectively. When ATRX-negative and DAXX-negative
tumours were compared, we identified 196 195 MVPs and
6708 DMRs. Taken together, these observations demon-
strate that genome-wide DNAm changes are associated
with a loss of DAXX expression and not a loss of ATRX. A
Benjamini–Hochberg (BH) adjusted P value of !0.05 that
corrected for multiple testing (false discovery rate) was used
throughout the various comparisons in order to identify
significantly methylated variable positions.
When ATRX-negative and DAXX-negative tumours
were compared as one group to normal pancreatic
samples, we identified 133 938 MVPs (BH adjusted
P value !0.05) and 4664 DMRs. A heat map that plotted
the top 1000 MVPs for this comparison demonstrated that
tumours were separated primarily by grade and thenhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0108
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Printed in Great Britainby ATRX or DAXX status (Fig. 1D). This was further
confirmed by the unsupervised clustering of G2 tumours
(eight DAXX-negative and five ATRX-negative cases)
alone against normal pancreatic control samples for the
top 1000 MVPs (Fig. 1E).
Of the 26 ATRX/DAXX-negative tumours (Fig. 1D),
20 samples (77%) were grouped into a distinct cluster.
However, six ATRX/DAXX-negative tumour samples had
intermediate methylation profiles and clustered with the
normal control pancreatic samples (Fig. 1D). Of them, five
were DAXX-negative (four G1 and one G2 tumours), and
one was ATRX-negative (a G2 tumour). When comparing
G2 tumours vs normal pancreas, there were 127 683 MVPs
(adjusted P value!0.05) and 4337 DMRs. However, for G1
vs normal pancreas, 31 480 MVPs and 300 DMRs were
identified. This indicates that low-grade (G1) tumours and
normal pancreas have similar methylation profiles.
Copy number variation (CNV) was determined in
ATRX/DAXX-negative and ATRX/DAXX-positive tumours
using DNA methylation data as previously described
(Feber et al. 2014). ATRX-negative and DAXX-negative
tumours demonstrated increased CNV as compared to
positive tumours (Fig. 1F). The genome-wide CNV rate was
quantified by determining the cumulative size of genomic
alterations (bp) in genomic regions that harboured a copy
number change of !K0.3 (for loss) or O0.3 (for gain).
Across the 23 ATRX/DAXX-positive primary tumours,
there were 1.4!109 bp of CNV in total (range per tumour
250 000–4.3!106, median 1.6!106). Across the 25 ATRX/
DAXX-negative primary tumours, there were 2.4!109 bp
of CNV in total (range per tumour 279 000–8.0!107,
median 1.5!107).
This is the first study of genome-wide DNA methyl-
ation in ATRX/DAXX-positive and ATRX/DAXX-negative
PNETs. The finding of a higher incidence of ATRX and
DAXX loss in intermediate-grade (G2) tumours may
account for the worse PFS and OS previously observed
(Marinoni et al. 2014); however, this finding requires
validation in a separate clinical cohort.
Genome-wide DNA methylation analysis identified
significantly more MVPs in DAXX-negative vs ATRX/
DAXX-positive tumours as compared to ATRX-negatives vs
ATRX/DAXX-positive tumours (4352 and 258 respectively).
This suggests that DAXX deficiency drives genome-wide
methylation changes, potentially through the functional
loss of H3.3 deposition (which binds DAXX in a highly
specific manner and loads it into DNA, whereas ATRX is a
co-factor that is involved in DAXX targeting chromatin) and
also through binding with the maintenance DNA methyl
transferase DNMT1 (Salomoni 2013). Mutations in H3.3Published by Bioscientifica Ltd.
Table 1 Clinical information and survival data
Patient
ID Sample ID Age Gender
Primary/
metastasis Grade
Protein
expression
lost
Total
follow-up
(months) PFS months OS months
ATRX/DAXX-negative tumours
1 1B2T_MG2_N 46 M Metastasis MG2 ATRX 54 51 54
3 3A28T2_G3_N 53 M Primary G3 ATRX 83 14 83
4 4A4T_G2_N 60 M Primary G2 DAXX 85 3 85
7 7C3T_MG1_N 81 F Metastasis MG1 ATRX 60 No progression Alive
8 8A2T_G1_N 49 F Primary G1 DAXX NA NA NA
8A3T1_G1_N G1 DAXX
8A3T2_G1_N G1 DAXX
11 11A1T_MG3_N 56 M Metastasis MG3 DAXX 20 16 20
12 12A3T1_MG2_N 62 F Metastasis MG2 DAXX 106 29 Alive
12A9T2_MG2_N Metastasis MG2 DAXX
12A10T_G2_N Primary G2 DAXX
13 13A12T_G2_N 73 M Primary G2 DAXX 55 15 Alive
13A13T_G2_N G2 DAXX
13A14T_G2_N G2 DAXX
13A19T_G2_N G2 DAXX
15 15A6T_G1_N 36 M Primary G1 DAXX 39 No progression Alive
19 19A7T_G1_N 30 F Primary G1 DAXX 54 51 54
21 21A4T_G2_N 66 M Primary G2 ATRX 39 No progression Alive
25 25A3T_G1_N 72 F Primary G1 DAXX 34 No progression Alive
26 26A2T_G2_N 21 M Primary G2 DAXX 21 No progression Alive
30 30C6T_G2_N 54 M Primary G2 ATRX 40 No progression Alive
31 31A4T_G2_N 74 F Primary G2 ATRX 24 No progression Alive
34 34A10T_G2_N 69 F Primary G2 DAXX NA NA NA
35 35A7T_G1_N 23 F Primary G1 DAXX 56 No progression Alive
36 36A3T_G2_N 57 M Primary G2 ATRX 72 14 72
37 37A3T1_G2_N 40 F Primary G2 ATRX 49 No progression Alive
38 38A4T_MG1_N 84 F Metastasis MG1 ATRX 66 No progression Alive
ATRX/DAXX-positive tumours
2 2B2T_G1_P 67 M Primary G1 No Loss 90 No progression Alive
5 5B5T2_G1_P 60 M Primary G1 No Loss 84 18 Alive
6 6A6T_G1_P 51 F Primary G1 No Loss 68 No progression Alive
6A8T1_G1_P G1 No Loss
6A8T2_G1_P G1 No Loss
6A8T3_G1_P G1 No Loss
9 9A9T2_G1_P 62 F Primary G1 No Loss 70 No progression Alive
10 10A7T_G1_P 45 F Primary G1 No Loss 54 No progression Alive
14 14B8T_G1_P NA NA Primary G1 No Loss 45 No progression Alive
17 17A2T_G1_P 53 F Primary G1 No Loss 47 No progression Alive
17A4T_G1_P G1 No Loss
18 18A4T_G1_P 64 F Primary G1 No Loss 40 No progression Alive
18A5T_G1_P G1 No Loss
20 20A3T_MG2_P 69 F Metastasis MG2 No Loss NA NA NA
22 22A6T_G1_P 72 M Primary G1 No Loss 18 No progression Alive
23 23D2T_G1_P 54 F Primary G1 No Loss 28 No progression Alive
23D7T_G1_P G1 No Loss
24 24A6T2_G2_P 47 F Primary G2 No Loss 84 36 Alive
27 27A6T_G2_P 58 M Primary G2 No Loss 33 No progression Alive
28 28A8T_G2_P 66 F Primary G2 No Loss 18 No progression Alive
29 29C4T_G1_P 71 F Primary G1 No Loss 26 No progression Alive
32 32B4T_G1_P 26 M Primary G1 No Loss 126 120 Alive
33 33E13T_G1_P 58 M Primary G1 No Loss 26 No progression Alive
37 37A4T_G2_P 40 F Primary G2 No Loss 49 No progression Alive
37A5T_G2_P G2 No Loss
39 39IIFT_G2_P 58 F Primary G2 No Loss 162 36 Alive
PFS, progression-free survival; OS, overall survival; NA, not available. The three samples from case 37 are different regions of the same surgical pathological
specimen. However, because of intra-tumoral heterogeneity, we observed that one sample was ATRX-negative, whereas the remaining two were
ATRX/DAXX-positive. For this reason, case 37 was not considered in the survival analysis.
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22 :3 L17occur commonly in paediatric brain tumours (Maze et al.
2014) and are known to lead genome-wide methylation
changes. Because ATRX interacts with the de novo DNA
methyl transferases DNMT3A/3L, its impact on genome-
wide methylation in ATRX-deficient PNETs is less marked.
In addition to investigating genome-wide DNA
methylation changes, CNV was determined from the
non-normalised methylated and unmethylated signal
intensities of the 450K array probes as previously described
(Feber et al. 2014). In keeping with previously reported data
in PNETs (Marinoni et al. 2014) and other solid tumours, we
found a higher incidence of CNV alterations in tumours
that had lost ATRX and DAXX (Heaphy et al. 2011). We also
demonstrated that ATRX/DAXX-negative tumours have a
poorer PFS as compared to ATRX/DAXX-positive cases (30
vs 85%, PZ0.0009) and that DAXX-negative tumours have
the poorest 5-year PFS overall (16%, PZ0.0005).
We demonstrated that even though they have
mutually exclusive mutations, ATRX- and DAXX-deficient
PNETs have distinct genome-wide DNA methylation
profiles. Loss of DAXX and not ATRX appears to be the
driver event in altering genome-wide methylation changes
in PNETs. Previous studies have analysed PNETs with ATRX
and DAXX loss in a single cohort, because mutations in
these genes are predominantly mutually exclusive. These
findings are also relevant to other neurological tumours
which are driven by ATRX and DAXX loss.
Finally, we demonstrated that DAXX-negative tumours
have the poorest 5-year PFS, and we therefore suggest more
aggressive disease course. However, further validation of
these findings is warranted in a separate clinical cohort.
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